Consistent with the role of NME4 as a metastasis suppressor in human subjects, low expression of NME4 is associated with shorter overall survival (i.e. poor prognosis) in patients with breast tumors or with several other tumor types [19]. Here, NME4 is linked to breast neoplasm.